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Abstract

o-Carbonyl arylboronic acids such as 2-formylphenylboronic acid (2-FPBA) are employed in biocompatible
conjugation reactions with the resulting iminoboronate adduct stabilized by an intramolecular N–B interaction.
However, few studies have utilized these reagents as active site-directed enzyme inhibitors. We show that 2FPBA is a potent reversible, slow-onset inhibitor of mandelate racemase (MR), an enzyme that has served as a
valuable paradigm for understanding enzyme-catalyzed abstraction of an 𝛼𝛼 -proton from a carbon acid substrate
with a high 𝑝𝑝𝐾𝐾𝑎𝑎 . Kinetic analysis of the progress curves for the slow onset of inhibition of wild-type MR using a
two-step kinetic mechanism gave 𝐾𝐾𝑖𝑖 and 𝐾𝐾𝑖𝑖∗ values of 5.1 ± 1.8 and 0.26 ± 0.08 μM, respectively. Hence,
wild-type MR binds 2-FPBA with an affinity that exceeds that for the substrate by ∼3000-fold. K164R MR was
inhibited by 2-FPBA, while K166R MR was not inhibited, indicating that Lys 166 was essential for inhibition.
Unexpectedly, mass spectrometric analysis of the NaCNBH3-treated enzyme–inhibitor complex did not yield
evidence of an iminoboronate adduct. 11B nuclear magnetic resonance spectroscopy of the MR·2-FPBA complex
indicated that the boron atom was sp3-hybridized (𝛿𝛿 6.0), consistent with dative bond formation. Surprisingly,
X-ray crystallography revealed the formation of an N ζ – B dative bond between Lys 166 and 2-FPBA with
intramolecular cyclization to form a benzoxaborole, rather than the expected iminoboronate. Thus, when ocarbonyl arylboronic acid reagents are employed to modify proteins, the structure of the resulting product
depends on the protein architecture at the site of modification.
The reaction between aldehydes and the amino group of a Lys residue or the amino terminus of a protein to
form an imine (Schiff base) has been widely employed to modify proteins; (1) however, the use of an aldehyde
that forms an imine that is stabilized through intramolecular interactions has been less widely employed. Early
examples include the use of salicylaldehyde to modify amino groups of proteins in which the imine is stabilized
via an intramolecular H-bond (2−5) or a metal chelate. (6−8) More recently, o-carbonyl arylboronic acids such as
2-formylphenylboronic acid [2-FPBA, 1 (Scheme 1A)] and 2-acetylphenylboronic acid (2-APBA) have been used

to modify the N-terminus of the protein (especially an N-terminal Cys) (9,10) or the ε − NH2 group of Lys
residues in proteins, (11−13) serving as the basis for several biocompatible conjugation reactions used in
chemical biology. (14−17) Because boron has a vacant p orbital, it is a Lewis acid and a strong electrophile.
Hence, either direct coordination of the lone pair of electrons on the imine nitrogen atom to the boron atom (2,
i.e., an N–B interaction) (11) or a solvent-inserted zwitterionic species (3, observed in protic
solvents) (18,19) stabilizes the enzyme–iminoboronate adduct by approximately 3–7 kcal/mol (Scheme
1A). (11,14) Furthermore, initial nucleophilic attack by the amine is facilitated by an O–B interaction in the ocarbonyl arylboronic acid reagent. (15) More recent strategies have focused on stabilizing iminoboronate-based
adducts by employing 𝛼𝛼-nucleophiles such as hydrazines, hydrazides, and hydroxylamines. (14−16,20)

Scheme 1

Considering the ability of 2-FPBA to interact with amino groups, we sought to explore 2-FPBA as an inhibitor of
mandelate racemase (MR). Indeed, there have been few reports of o-carbonyl arylboronic acids as purely active
site-directed enzyme inhibitors. (21) MR is the archetype of the enolase superfamily and has served as a useful
paradigm for understanding how enzymes deprotonate carbon acid substrates with relatively high
𝑝𝑝𝐾𝐾𝑎𝑎 values. (22−24) MR possesses a Lysa − X − Lysb (KXK) motif at its active site, which is a characteristic
feature of enzymes in the MR and d-glucarate dehydratase subgroups of the enolase
superfamily. (25) Lysb serves as a Brønsted base to catalyze the deprotonation of the substrate (S)-mandelate
(Scheme 1B), and Lysa is believed to modulate the 𝑝𝑝𝐾𝐾𝑎𝑎 of Lysb . (26,27) Because 3-hydroxypyruvate was shown
previously to form an imine with Lys 166 of MR, (28) which irreversibly inactivated the enzyme through
formation of an aldehyde/enol(ate) adduct, we anticipated that the enzyme might be susceptible to inhibition
by 2-FPBA due to the propensity of this reagent to modify Lys residues through imine formation. Consequently,
we rationalized that 2-FPBA should be bound with a high affinity as we recently demonstrated for phenylboronic
acid (PBA) (29) and form a stabilized iminoboronate through Schiff base formation with one of the Lys residues
present in the KXK motif. Herein, we show that 2-FPBA is the first reversible slow-onset inhibitor of MR, binding
with an affinity that exceeds that of PBA. Most surprisingly, X-ray crystallography revealed that, unlike the
MR·PBA complex that formed a weak N ε2 – B dative bond with His 297 at the active site, MR formed an N–B
dative bond between Lys 166 and the boronic acid group accompanied by intramolecular cyclization to form a
benzoxaborole derivative, rather than the anticipated iminoboronate. These findings furnish a caveat that
alternative products other than iminoboronates may arise when o-carbonyl arylboronic acid reagents are
employed to modify proteins depending on the protein architecture at the site of modification.

Materials and Methods
General

Benzohydroxamate (BzH) and all other reagents, unless mentioned otherwise, were purchased from SigmaAldrich Canada Ltd. (Oakville, ON). 2-Formylphenylboronic acid was purchased from TCI America (Portland, OR),
and 2-acetylphenylboronic acid, 4-chloro-2-formyphenylboronic acid (4-Cl-2-FPBA), and 2-carboxyphenylboronic
acid (2-CPBA) were purchased from Combi-Blocks (San Diego, CA). DNA oligonucleotide primers were obtained
from Integrated DNA Technologies (Coralville, IA). Circular dichroism (CD) spectral measurements were taken
using a JASCO J-810 spectropolarimeter (Jasco Inc., Easton, MI). 11B nuclear magnetic resonance (NMR, 160.5
MHz) spectra were recorded using a Brüker AVANCE 500 NMR spectrometer at the Dalhousie Nuclear Magnetic
Resonance Research Resource (NMR-3) Centre. Mass spectrometry was conducted at the AIMS Mass
Spectrometry Laboratory (Department of Chemistry, University of Toronto, Toronto, ON).

Site-Directed Mutagenesis

The MR variants K164R and K166R were created using site-directed mutagenesis. For these MR variants, the
pET-52b(+)-wtMR plasmid (30) was used as the template for site-directed mutagenesis using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and following the protocols described by the
manufacturer. Reactions were conducted using PfuTurbo DNA polymerase (Bio Basic Inc., Markham, ON). The
forward (F) and reverse (R) synthetic deoxyoligonucleotide primers used to incorporate the desired mutation
into the open reading frames encoding the K164R and K166R MR variants were as follows: 5′GGATTCCGGGCGGTTAGGACCAAGATCGGC-3′ (F, K164R), 5′-GCCGATCTTGGTCCTAACCGCCCGGAATCC-3′ (R,
K164R), 5′-CCGGGCGGTTAAGACCCGGATCGGCTATCCG-3′ (F, K166R), and 5′CGGATAGCCGATCCGGGTCTTAACCGCCGG-3′ (R, K166R). The modified codons are underlined, and the altered
bases are shown in boldface. After site-directed mutagenesis, mutant plasmids were used to transform
competent Escherichia coli DH5α cells for plasmid maintenance. Each mutant open reading frame was
sequenced using commercial automated DNA sequencing (Robarts Research Institute, London, ON) to ensure
that no other alterations in the nucleotide sequence had been introduced.

Enzyme Purification

StrepII-tagged recombinant variants of MR (wild-type MR, K164R MR, and K166R MR) were overexpressed in
and purified from E. coli BL21(DE3) cells transformed with the appropriate plasmid as described
previously. (30) These constructs encode the wild-type or mutant MR gene products as fusion proteins with an
N-terminal StrepII tag (MASWSHPQFEKGALEVLFQGPGYHM1-MR, where M1 denotes the initial Met of either the
wild-type or variant MRs and the StrepII tag is underlined). Briefly, two starter cultures containing lysogeny
broth (LB, 5 mL) and ampicillin (50 μg/mL) were inoculated with a glycerol stock solution (10 μL each) and
incubated overnight at 37 °C while being continuously shaken at 225 rpm. Both starter cultures were used to
inoculate LB medium (1.0 L) containing ampicillin (50 μg/mL) in a 2-L Erlenmeyer flask. Cultures producing wildtype MR were incubated for ∼8 h at 37 °C, and cultures producing either K164R or K166R MR were incubated for
2 h at 37 °C followed by 24 h at 25 °C, each with continuous shaking at 225 rpm (no induction by IPTG was used
for expression of any enzyme variants). (30) The cells were then harvested by centrifugation (3000g, 10 min, 4
°C), and the cell pellet was stored at −20 °C until further processing. Two frozen pellets were thawed and
resuspended in ice-cold wash buffer [Tris-HCl buffer (100 mM, pH 8.0) containing NaCl (150 mM) and EDTA (1
mM)]. The cells were lysed using sonication with 6 × 30 s bursts with 1 min cooling intervals, at a constant power
setting of 5.5 using a Branson Sonifier 250 instrument. The soluble cell extract was clarified by centrifugation
(110000g, 30 min, 4 °C), and the supernatant (30–40 mL) was loaded onto a column containing Strep-Tactin
Superflow affinity resin (10 mL) (IBA GmbH, Göttingen, Germany) connected to an ÄKTA FPLC instrument. After
the column had been washed with wash buffer (5 × the column volume), the enzyme was eluted with wash

buffer containing desthiobiotin (2.5 mM). Upon elution, the enzyme was dialyzed against assay buffer [Na+HEPES buffer (100 mM, pH 7.5) containing MgCl2 (3.3 mM)] and stored at −20 °C. The purity of the enzyme
(≥99%) was assessed using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (12% acrylamide) with
staining by Coomassie blue R-250. (31) Protein concentrations were determined from the intrinsic enzyme
absorbance at 280 nm using extinction coefficients (ε) of 53400 M–1 cm–1 for all MR variants, which were
estimated using the ProtParam program from ExPasy (http://web.expasy.org/protparam/). (32) The StrepII tag
was not removed from the enzymes.

MR Assays

MR activity was assayed using a CD-based assay by following the change in ellipticity of mandelate at 262 nm
with a 1-cm light path (unless otherwise indicated) as described by Sharp et al. (33) All kinetic assays, including
inhibition experiments, were conducted at 25 °C in Na+-HEPES buffer (0.1 M, pH 7.5) containing MgCl2 (3.3 mM).
The concentration of (R)- or (S)-mandelate for assays ranged from 0.25 to 15.0 mM, and the concentrations of
wild-type MR, K164R MR, and K166R MR were 3.0, 400, and 3000 nM, respectively. Reactions (total volume of
2.0 mL) were initiated by the addition of the enzyme solution (100 μL) containing 0.1% (w/v) bovine serum
albumin. The apparent kinetic constants Vmax (= 𝑘𝑘cat [E]T ) and 𝐾𝐾𝑚𝑚 were determined by fitting eq 1 to the initial
velocity data using nonlinear regression analysis and KaleidaGraph version 4.02 from Synergy Software (Reading,
PA). All kinetic parameters were determined in triplicate, and average values are reported. The reported errors
are the standard deviations.

(1)

𝑣𝑣i =

𝑉𝑉max [S]
𝐾𝐾m + [S]

Inhibition Studies

The ability of a variety of aldehydes to inhibit wild-type MR was assessed by measuring the relative activity
(i.e., 𝑣𝑣i /𝑣𝑣0 ) of wild-type MR (3.0 nM) with (S)-mandelate (2.0 mM) as the substrate and varying concentrations
of benzaldehyde (1.0 μM to 5.0 mM), 2-carboxybenzaldehyde (1.0 μM to 2.0 mM), salicylaldehyde (1.0 μM to
2.0 mM), and 2-formylbenzenesulfonate (1.0 μM to 5.0 mM). The IC50 values for inhibition of wild-type MR (3.0
nM) at pH 7.0, 7.5, and 8.0; K164R MR (300 nM); and K166R MR (2300 nM) by 2-FPBA (0.2–20.0, 1.5–10.5, and
1.0–5000.0 μM, respectively) were determined by measuring the relative velocities (i.e., 𝑣𝑣s /𝑣𝑣0) with (S)mandelate (10.0 mM) as the substrate at the indicated concentrations of 2-FPBA. The velocities used were those
attained at steady state (i.e., 𝑣𝑣s obtained after full onset of inhibition) while following the reaction for 10 min.
The relative velocities for inhibition of wild-type MR (3.0 nM) were also determined for 4-Cl-2-FPBA (0.5–4.0
μM), 2-APBA (50.0–750.0 μM), and 2-CPBA (0.1–3.8 mM) in a similar manner using (R)-mandelate (10.0 mM) as
the substrate. At higher inhibitor concentrations, the light path length was decreased from 1.0 to 0.5 or 0.2 cm
when appropriate. IC50 values were determined by fitting the observed relative velocities (𝑣𝑣i /𝑣𝑣0 or 𝑣𝑣s /𝑣𝑣0 when
slow-onset inhibition was observed) to eq 2.

(2)

𝑛𝑛
𝑣𝑣i
𝑣𝑣s
IC50
�or � = 𝑛𝑛
𝑣𝑣0
𝑣𝑣0
IC50 + [I]𝑛𝑛

The reversibility of inhibition by 2-FPBA was evaluated by measuring the recovery of enzyme activity after
dilution. Wild-type MR (300 nM) was incubated with 2-FPBA (6.0 μM) at 25 °C, and at various times (2, 7, 11, 16,
20, 24, 29, 44, and 60 min), an aliquot was removed and diluted 100-fold into assay buffer containing (S)-

mandelate (final concentration of 2.0 mM) and the steady state velocity was then measured using the standard
MR assay.
The slow onset of inhibition by 2-FPBA was measured by following the change in the ellipticity at 262 nm over 15
min using a quartz cuvette with a 1.0-cm light path length. The reaction was initiated by addition of either wildtype MR (3.0 nM) or K164R MR (300.0 nM) to a solution of (S)-mandelate (5.0 mM) containing varying
concentrations of 2-FPBA (0.1–20.0 μM) in assay buffer. Equation 3 was used to fit all of the resulting progress
curves simultaneously using nonlinear regression analysis and OriginPro version 9.0 (OriginLab Inc.,
Northampton, MA), where 𝑣𝑣i , 𝑣𝑣s , and 𝑘𝑘obs are defined by eqs 4–6, respectively, in accord with the two-step,
competitive inhibition kinetic mechanism shown in Scheme 2A. (34,35)

(3)

[P] = 𝑣𝑣s 𝑡𝑡 +
𝑣𝑣i =

(4)

𝑣𝑣i − 𝑣𝑣s
�1 − e−𝑘𝑘obs 𝑡𝑡 �
𝑘𝑘obs

𝑘𝑘cat [E]T [S]
[I]
𝐾𝐾m �1 + 𝐾𝐾 � + [S]
i

(5)

𝑘𝑘cat [E]T [S]
[I]
𝐾𝐾m �1 + ∗ � + [S]
𝐾𝐾i

(6)

[I]
𝐾𝐾i ∗
= 𝑘𝑘6 �
�
[I]
1 + 𝐾𝐾
i

𝑣𝑣s =

𝑘𝑘obs

1+

For the inhibition of K164R MR by 2-FPBA, the initial rate (vi) was found to be independent of the concentration
of 2-FPBA and the progress curves were fit to a single-step, slow-onset inhibition model (Scheme 2B) where eqs
7–9 replaced eqs 4–6, respectively. (34,35)

(7)

𝑣𝑣i =
𝑣𝑣s =

(8)

(9)

𝑘𝑘cat [E]T [S]
𝐾𝐾m + [S]

𝑘𝑘cat [E]T [S]
[I]
𝐾𝐾m �1 + � + [S]
𝐾𝐾i

𝑘𝑘obs = 𝑘𝑘4 �1 +

[I]
�
𝐾𝐾i

The two- and one-step models were chosen to fit the slow-onset inhibition for wild-type MR and K164R MR,
respectively, because these models afforded the fits with better correlation coefficients.
Scheme 2

Inhibition experiments with benzohydroxamate (BzH) were conducted at 25 °C in Na+-HEPES buffer (0.1 M, pH
7.5) containing MgCl2 (3.3 mM). The concentration of (S)-mandelate in these assays ranged from 0.5 to 10.0
mM. The concentrations of BzH used were 10, 20, and 30 μM with wild-type MR (3.0 nM); 50, 75, and 100 μM
with K164R MR (200 nM); and 50, 100, and 200 μM with K166R MR (3000 nM). Competitive inhibition constants
(𝐾𝐾𝑖𝑖 ) for BzH were determined from plots of the apparent 𝐾𝐾𝑚𝑚 /𝑉𝑉max values versus inhibitor concentration in
accord with eq 4. (36)

Mass Spectrometry (MS)

Samples of MR were prepared for MS by exchanging assay buffer with ammonium acetate (10 mM, pH 7.5). The
final concentrations of both the enzyme and the inhibitor were 10 μM. Mass spectra were recorded on an
AB/Sciex QStarXL mass spectrometer equipped with an ion spray source operated in positive ion mode. Ions
were scanned in the range of m/z 800–4000 with accumulation times of 1 s per spectrum with no interscan time
delay. Experiments were conducted to trap the imine adduct using NaCNBH3. Wild-type MR (10 μM) in assay
buffer was incubated with 2-FPBA (10 or 100 μM) for 30 min and then reacted with NaCNBH3 (2.5 mM)
overnight at 4 °C.

B NMR Spectroscopy

11

All NMR spectra were recorded at 25 °C in Na+-HEPES buffer (0.1 M, pH 7.5) containing MgCl2 (3.3 mM) and D2O
(10%). Chemical shifts (δ) of the signals arising from 11B are reported relative to an external standard of
BF3·OEt2 (δ 0.00). Samples were measured in 5-mm quartz tubes (Sigma-Aldrich Canada Ltd.) to reduce the
background signal arising from boron in borosilicate glass. For the spectra of 2-FPBA in the presence of MR, the
concentration of 2-FPBA was fixed at 400 μM and the spectra were recorded with varying amounts of wild-type
MR added to the solution (0–425 μM). To verify that 2-FPBA was bound at the active site of MR, the competitive
inhibitor BzH was added to the sample in excess (5 mM) to displace the 2-FPBA from the active site. As a model
reference reaction for possible imine formation, the 11B NMR spectra were also recorded for 2-FPBA (5.0 mM) in
the absence and presence of 5, 15, 500, and 3000 mM ethylamine hydrochloride, all in Na+-HEPES buffer (0.1 M,
pH 7.5) containing MgCl2 (3.3 mM) and D2O (10%). In addition, the effect of mandelate on the 11B NMR spectrum
of 2-FPBA was examined. The 11B NMR spectra were recorded for 2-FPBA (5.0 mM) in the presence of 5.0 and

50.0 mM (S)-mandelate in Na+-HEPES buffer (0.1 M, pH 7.5) containing MgCl2 (3.3 mM) and D2O (10%). The
background boron signal arising from borosilicate glass in the spectrometer probe was reduced in the spectra
using Whittaker smoothing. (37)

Protein Crystallization

Crystals of wild-type MR were grown in the presence of 2-FPBA by the sitting-drop vapor diffusion method
against a 500 μL reservoir volume. The protein solution and reservoir solution were mixed in a 1:1 ratio to a final
volume of 10 μL. Crystals grew spontaneously at 21 °C. The reservoir solution consisted of PEG 3350 [4% (w/v)]
and Bis-Tris Propane (BTP; 50 mM, pH 7.0). The protein solution consisted of wild-type MR (6 mg/mL) purified as
described above, 2-FPBA (1.0 mM), MgCl2 (3.3 mM), and Na+-HEPES buffer (50 mM, pH 7.5). The resulting
cubelike crystals (∼50 μm × 40 μm × 40 μm) grew to full size within 15–20 days. Crystals were harvested and
transferred to a synthetic stabilizing solution consisting of PEG 4K [8% (w/v)], BTP (80 mM, pH 7.0), ethylene
glycol [5% (w/v)], 2-FPBA (0.77 mM), MgCl2 (1.65 mM), and Na+-HEPES buffer (25 mM, pH 7.5). These stabilized
crystals were equilibrated in the synthetic stabilizing solution for 5 min and then transferred directly to a
cryoprotectant solution consisting of PEG 4K [10% (w/v)], BTP (80 mM), ethylene glycol [20% (w/v)], 2-FPBA (0.8
mM), MgCl2 (1.58 mM), and Na+-HEPES buffer (24 mM, pH 7.5). The cryoprotected crystals were flash-frozen in a
stream of nitrogen gas at 100 K.

Data Collection, Structure Determination, and Refinement

X-ray diffraction data were collected at the Life Sciences Collaborative Access Team beamline 21-ID-D at the
Advanced Photon Source, Argonne National Laboratory, on a Dectris Eiger 9M detector with an X-ray
wavelength of 1.1271 Å. A total of 3600 diffraction images were collected at an oscillation angle of 0.1° (360°
total) with an exposure time of 0.010 s. These images were processed using the autoPROC software
workflow, (38) which merged and scaled the isotropic data in AIMLESS (39) with the programs
TRUNCATE (40) and UNIQUE (41) to determine the resolution limit. The phases were determined by the
molecular replacement method, using the wild-type MR enzyme with bound BzH [Protein Data Bank (PDB)
entry 3UXK] as the search model, (42) with the program Phaser. (43) The molecular replacement models were
extended by several rounds of manual model building with COOT (44) and refinement with
Phenix.Refine. (45) The X-ray/stereochemistry weight was automatically optimized to 3.0 in the final rounds of
refinement. Noncrystallographic restraints between each monomer were applied for the first round of
refinement but were relieved for subsequent rounds. Water molecules were added to the model in COOT and
Phenix.Refine with subsequent manual verification. The final refined ligand coordinates for the 2FPBA/benzoxaborole adduct were optimized for structural refinement using eLBOW (electronic ligand building
and optimization workbench), (46) and a linkage restraint was applied between the ε-nitrogen of Lys 166 and
the boron atom of the 2-FPBA/benzoxaborole adduct during the final stages of refinement. The 2FPBA/benzoxaborole adduct was modeled with full occupancy at each of the eight active sites. Data collection
and processing statistics are listed in Table S1.

Results and Discussion
Inhibition Kinetics

Surprisingly, the reaction progress curves obtained upon initiation of the racemization reaction by addition of
wild-type MR to solutions containing (S)-mandelate (5.0 mM) and various concentrations of 2-FPBA revealed an
initial “burst” phase followed by a time-dependent decrease in reaction rate until a steady state velocity (𝑣𝑣s )
was obtained that varied as a function of the inhibitor concentration (Figure 1A). Similarly, when assays were
initiated with a substrate after incubation of the enzyme with 2-FPBA for 5 min, an initial lag phase was
observed. Our initial inhibition studies with 2-FPBA in the presence of (S)-mandelate (10.0 mM) revealed that 2-

FPBA was a potent inhibitor of wild-type MR, exhibiting an apparent IC50 value of 3.1 ± 0.3 μM based on the
final steady state velocities (𝑣𝑣s ) (Table 1 and Figure S1), although not irreversible because full activity could be
readily regained upon dilution. This degree of inhibition is similar to that observed for the
intermediate/transition state analogue inhibitors BzH (𝐾𝐾𝑖𝑖 = 9.3 μM), (47) Cupferron (𝐾𝐾𝑖𝑖 = 2.7
μM), (48) and N-hydroxyformanilide (𝐾𝐾𝑖𝑖 = 2.8 μM), (48) as well as PBA (𝐾𝐾𝑖𝑖 = 1.8 μM). (29) Two possible
kinetic mechanisms were considered to describe the observed slow-onset inhibition: (1) initial reversible binding
of the inhibitor to the enzyme to yield an EI complex, which then undergoes reversible isomerization to form a
new complex E*I (Scheme 2A), and (2) reversible binding of the inhibitor to the enzyme to form an EI complex in
which the magnitudes of k3 and k4 are such that the equilibrium is established slowly relative to the rate of
enzyme turnover (Scheme 2B). (34,35,49) In both cases, a competitive inhibition model was employed on the
basis of BzH displacing the inhibitor in 11B NMR spectroscopy studies and the results obtained from X-ray
crystallography experiments (vide infra). The kinetic data for the inhibition of wild-type MR by 2-FPBA were
analyzed in accord with Scheme 2A and gave an apparent 𝐾𝐾𝑖𝑖 value of 5.1 ± 1.8 μM, 𝐾𝐾𝑖𝑖∗ = 0.26 ± 0.08 μM,
and 𝑘𝑘6 = (4.2 ± 2.4) × 10–4 𝑠𝑠 –1 at pH 7.5 (Table 2). Equation 10 was used to calculate an apparent value
of 𝑘𝑘5 [(7.8 ± 5.6) × 10–3 𝑠𝑠 –1 ].
(10)

𝐾𝐾i∗ =

𝐾𝐾i 𝑘𝑘6
[E][I]
=
𝑘𝑘5 + 𝑘𝑘6 [EI] + [E ∗ I]

Despite the large error in 𝑘𝑘5 and 𝑘𝑘6 that arises from the lack of sensitivity of the CD-based assay, it is clear that
wild-type MR binds 2-FPBA with an affinity that exceeds that for the substrate [for (S)-mandelate, K S ≈ K m =
0.7 mM (Table 2)] (50) by ∼3000-fold (i.e., 𝐾𝐾𝑚𝑚 /𝐾𝐾𝑖𝑖∗ ). Interestingly, we found that structurally similar o-carbonyl
phenylboronic acids were not as potent as inhibitors of MR (Table 1 and Figure S1). For example, 2-APBA was a
modest inhibitor (IC50 = 392 μM) and 2-carboxyphenylboronic acid (2-CPBA) (51) was an extremely weak
inhibitor of wild-type MR (IC50 ∼ 19 mM). Clearly, the additional steric bulk arising from the methyl group and
oxygen impairs binding. However, 4-chloro-2-FPBA was a slightly better inhibitor (IC50 = 1.65 μM) than 2-FPBA
(IC50 = 3.1 μM), which is in accord with the enhanced inhibition previously reported for 4-chloro-PBA relative
to PBA. (29) Aromatic aldehydes, including benzaldehyde (5.0 mM), 2-carboxybenzaldehyde (2.0 mM),
salicylaldehyde (2.0 mM), and 2-formylbenzenesulfonate (5.0 mM), did not significantly inhibit wild-type MR up
to the concentrations indicated (data not shown). Because these aromatic aldehydes are not hydrated to a
significant extent in water, (52,53) their inability to inhibit MR suggests that the boronic acid group plays an
important role in the binding affinity, which is not surprising considering the potent inhibition of MR exhibited
by PBA. (29) Interactions with the boronic acid group could arise through formation of a weak N–B dative bond
with His 297 as observed for PBA (29) or perhaps through formation of an intramolecular N–B interaction with
an imine [2 (Scheme 1A)] or an intermolecular N–B interaction with a Lys at the active site.

Figure 1. Progress curves for the onset of inhibition of (A) wild-type MR and (B) K164R MR by 2-FPBA. The curves
shown for wild-type MR (3.0 nM) and K164R MR (300 nM) are fits of eq 3 to the amount of (S)-mandelate (initial
concentration of 5.0 mM) consumed over time as described in Materials and Methods. The corresponding
concentrations (micromolar) of 2-FPBA are shown to the right of each line, and the values determined
for 𝐾𝐾𝑖𝑖 and 𝐾𝐾𝑖𝑖∗ are listed in Table 2.
Table 1. IC50 Values for Various o-Carbonyl Phenylboronic Acids
MR variant
𝐈𝐈𝐈𝐈𝟓𝟓𝟓𝟓 (μM)a
Inhibition by 2-FPBA
wild-type
pH 7.0
7.51 ± 0.59
pH 7.5
3.12 ± 0.30
pH 8.0
2.30 ± 0.33
K164R
7.21 ± 0.54
K166R
no inhibition observed
Inhibition by 4-Cl-2-FPBA
wild-type
1.65 ± 0.08
Inhibition by 2-APBA
wild-type
392 ± 30
Inhibition by 2-CPBA
wild-type
∼19000b

IC50 values determined in triplicate using the steady state initial velocities. Average values are reported, and
the error is the standard deviation.
b
IC50 value approximated on the basis of 17% inhibition observed at 3.8 mM 2-CPBA, 10 mM (R)-mandelate,
a 𝐾𝐾𝑚𝑚 of 0.9 mM, and assuming competitive inhibition.
a

Table 2. Kinetic Parameters for Wild-Type MR, K164R MR, and K166R MR with (R)- and (S)-Mandelate
kinetic parametera wild-type MR
K164R MR
K166R MR
R→S
𝐾𝐾𝑚𝑚 (mM)
0.9 ± 0.2
1.4 ± 0.2
1.0 ± 0.2
𝑘𝑘cat (s– 1)
670 ± 40
4.6 ± 0.2
0.42 ± 0.05
𝑘𝑘cat /𝐾𝐾𝑚𝑚 (M–1 s–1)
(7.4 ± 0.7) × 105
(3.3 ± 0.4) × 103 (4.2 ± 1.0) × 102
S→R
𝐾𝐾𝑚𝑚 (mM)
0.7 ± 0.1
1.2 ± 0.2
1.4 ± 0.2
–1
𝑘𝑘cat (s )
590 ± 30
4.2 ± 0.4
0.55 ± 0.09
𝑘𝑘cat /𝐾𝐾𝑚𝑚 (M–1 s–1)
(8.42 ± 1.27) × 105
(3.5 ± 0.6) × 103 (3.9 ± 0.9) × 102
𝐾𝐾eqb
1.1 ± 0.2
1.1 ± 0.2
0.9 ± 0.3
Inhibition Studies
𝐾𝐾𝑖𝑖 (BzH, μM)
12 ± 2
54 ± 9
99 ± 9
𝐾𝐾𝑖𝑖 (2-FPBA, μM)
5.1 ± 1.8
0.8 ± 0.2
no inhibition
∗
𝐾𝐾𝑖𝑖 (2-FPBA, μM)
0.26 ± 0.08
–
no inhibition
a
Kinetic parameters determined in triplicate with average values reported. The error is the standard deviation.
b
Calculated using the Haldane relationship in which 𝐾𝐾eq = [𝑅𝑅]⁄[𝑆𝑆] = (𝑘𝑘cat ⁄𝐾𝐾m )𝑆𝑆→𝑅𝑅 ⁄(𝑘𝑘cat ⁄𝐾𝐾m )𝑅𝑅→𝑆𝑆 .

Role of the Active Site Lysine Residues

To assess the possibility of formation of an imine adduct or an intermolecular N–B interaction with 2-FPBA, we
investigated the role of Lys 164 and Lys 166 located at the active site. Consequently, we purified and
characterized the K164R and K166R MR variants (Table 2). The K164R and K166R MR variants exhibited marked
reductions in catalytic efficiency (𝑘𝑘cat ⁄𝐾𝐾m ) of 224- and 1762-fold in the R → S reaction direction and 241- and
2159-fold in the S → R reaction direction, respectively. Indeed, the K166R variant had been characterized
previously by Gerlt and co-workers (54) and our kinetic constants are in excellent agreement with their results.
Both K164R and K166R MRs were competitively inhibited by BzH, with 𝐾𝐾𝑖𝑖 values of 54 ± 9 and 99 ± 9 μM,
respectively. The loss of binding affinity corresponded to a decrease in catalytic efficiency as demonstrated
previously for this intermediate/transition state analogue inhibitor. (42,47)
As shown in Figure S1, K166R MR was not inhibited by 2-FPBA while K164R MR was strongly inhibited (IC50 =
7.2 μM), although not to the same extent as the wild-type enzyme (IC50 = 3.1 μM). This observation
supported the notion that 2-FPBA reacted with Lys 166 at the active site. As observed for wild-type MR, the
onset of inhibition of the K164R variant was time-dependent (Figure 1B). However, unlike inhibition of wild-type
MR, the initial velocities (vi) were not significantly different for K164R MR in the presence of 2-FPBA.
Consequently, the inhibition kinetics were fit using the kinetic mechanism shown in Scheme 2B. Interestingly,
nearly all reported examples of slow-onset inhibition tend to follow the two-step kinetic model shown
in Scheme 2A, with few examples of a single-step mechanism. (55) The values of 𝐾𝐾𝑖𝑖 , 𝑘𝑘3 , and 𝑘𝑘4 were 0.8 ± 0.2
μM, 188 ± 89 M–1 s–1, and (1.5 ± 0.6) × 10–4 s–1, respectively. Hence, K164R MR bound 2-FPBA with an affinity
that was reduced by ∼3-fold relative to that observed for wild-type MR (i.e., 𝐾𝐾𝑖𝑖 /𝐾𝐾𝑖𝑖∗ ).

Mass Spectrometry and 11B NMR Spectroscopy

Direct evidence of the formation of an MR·2-FPBA adduct using mass spectrometry was inconclusive (Figure S2)
likely because of the reversibility of the inhibition leading to rapid dissociation during the aerosolization
process. (13) Interestingly, attempts to trap a more stable adduct by reducing the putative imine with
NaCNBH3 proved to be unsuccessful, suggesting that the adduct might not be an imine. Consequently, we
utilized 11B NMR spectroscopy to investigate the interaction between MR and 2-FPBA. This approach has been
employed to study the interaction of boronic acid-bearing inhibitors with a variety of proteases, (56−64) βlactamase, (65) and γ-glutamyl transpeptidase. (66) In the absence of enzyme, the boron in 2-FPBA exhibited
signals with chemical shifts of 29.8 and 8.5 ppm in assay buffer (Figure 2). This observation is in agreement with
those of Gutiérrez-Moreno et al., (67) who reported chemical shifts of 29.3 and 8.6 ppm for 2-FPBA in neutral
solutions corresponding to the trigonal neutral R-B(OH)2 group [1 (Scheme 1A)] and the tetrahedral anionic RB(OR)(OH)2– group formed from the reversible cyclization to the benzoxaborole (4), respectively. The
observation of the presence of both signals suggests that the ionization of 2-FPBA is a slow process on the NMR
time scale, possibly due to the accompanying cyclization. (67) The signal at 29.8 ppm was weak relative to the
signal at 8.5 ppm because only 39% of 2-FPBA (p𝐾𝐾aB = 7.3) (67) exists in the neutral form at pH 7.5. The low
signal-to-noise ratio arose because of the requirement to use concentrations of the inhibitor approximately
stoichiometric with the enzyme concentration. Upon addition of the enzyme, a new peak was observed at 6.0
ppm, which was also the sole peak present when the enzyme was in slight excess. Surprisingly, this chemical
shift differed markedly from that observed for the MR·PBA complex, which exhibited an 11B NMR signal at 0.97
ppm. Furthermore, this chemical shift was slightly more upfield relative to the 11B chemical shift of ∼7.4 ppm
observed when we examined the effect of a large excess of ethylamine hydrochloride on the chemical shift of
the 11B NMR signal of 2-FPBA under our assay conditions (Figure S3). These observations indicate that the bound
species has considerable negative charge associated with the boron atom, which is characteristic of an anionic
tetrahedral boronate anion (68) but is often interpreted as evidence for iminoboronate
formation. (69) Consequently, the electronic configuration around the boron in the MR·2-FPBA complex differs
from that of the MR·PBA complex, suggesting that the two boronic acid species are bound differently at the
active site.

Figure 2. 11B NMR spectra of free 2-FPBA and 2-FPBA bound to MR. The 11B NMR spectra of (A) 2-FPBA (400 μM)
in the absence of enzyme, (B) 2-FPBA (400 μM) in the presence of wild-type MR (200 μM), (C) 2-FPBA (400 μM)
in the presence of approximately equimolar wild-type MR (425 μM), and (D) 2-FPBA (400 μM) in the presence of

wild-type MR (425 μM) and excess BzH (5.0 mM) are shown. All solutions contained Na+-HEPES buffer (0.1 M, pH
7.5), MgCl2 (3.3 mM), and D2O (10%). The pH of these solutions was adjusted to 7.5 using NaOH (6 M). The
indicated 11B chemical shifts are relative to that of the external standard BF3·OEt2.
Addition of a large excess of the competitive, intermediate/transition state analogue inhibitor BzH ([BzH] =
417𝐾𝐾𝑖𝑖 ) resulted in total displacement of the 2-FPBA from the active site, regenerating the 11B NMR signals
associated with free 2-FPBA (Figure 2). These observations further demonstrated that the interaction of 2-FPBA
with MR occurred at the active site and was freely reversible. Finally, as shown in Figure S3, we used 11B NMR
spectroscopy to rule out the possibility that inhibition arose from formation of an adduct with
mandelate. (70,71)

Structure of the MR·2-FPBA Complex

To obtain a detailed understanding of how 2-FPBA inhibits MR, we determined the X-ray crystal structure of the
MR·2-FPBA complex at 1.91-Å resolution. The complex crystallized as a homooctomer in space group C121
(Table S1). The individual subunits were similar, with root-mean-square deviations (rmsds) for structural
alignments between the 𝛼𝛼 -carbon atoms of the individual subunits ranging from 0.092 to 0.157 Å. The electron
density for the 2-FPBA ligands was very well-defined over the entire molecule in all eight active sites. The
electron density between the ε − NH2 group of Lys 166 and the bound 2-FPBA was continuous, consistent with
formation of a covalent adduct and the requirement for Lys 166 for potent inhibition (Figure 3A). Initially, we
modeled the imine adduct (2) or the aminol adduct [S9 (Scheme S1)] at the active site, assuming that Lys 166
had added to the aldehyde group. However, these models failed to fit the electron density well even when
partial occupancies were considered, nor did modeling the Lys 166-NH2-boronic acid complex [6 (Scheme 3)]
conform to the observed electron density. Recognizing that 2-FPBA can undergo reversible cyclization to form a
benzoxaborole, (67) we modeled the ligand as the product of the nucleophilic addition of the ε − NH2 group of
Lys 166 to the boronic acid group with intramolecular addition of a hydroxyl group of the boronic acid to the
aldehyde. This cyclic benzoxaborole [7, i.e., 1,3-dihydro-1,3-dihydroxy[c][2,1]oxaborole (Scheme
3)] (72) afforded an excellent fit to the observed electron density. To the best of our knowledge, this is the first
report of this type of adduct for 2-FPBA interacting with a protein.

Figure 3. X-ray structure of the 2-FPBA/benzoxaborole adduct at the active site of MR. (A) Stereoview of the
representative electron density overlaid on the final refined model for the active site of chain A. The electron
density maps represent the final calculated 2𝐹𝐹𝑂𝑂 – 𝐹𝐹𝐶𝐶 map (blue, contoured at 1𝜎𝜎) and the simulated annealing

omit 𝐹𝐹𝑂𝑂 – 𝐹𝐹𝐶𝐶 map (green, contoured at 3σ) with all atoms of 2-FPBA, Mg2+, Lys 166, and both waters
coordinating the Mg2+ ion omitted from the model. (B) Stereoview of the molecular interactions contributing to
binding the 2-FPBA/benzoxaborole adduct at the active site of MR (chain A). The carbon atoms are colored
green for the metal-chelating residues, gray for the Brønsted acid–base catalysts, and white for additional
interacting residues. Interactions are represented with dashed lines. Distances to the ligand are indicated in
angstroms. (C) Stereoview of a structural overlay of the active site of MR with the 2-FPBA/benzoxaborole adduct
(CPK colors, gray carbon atoms) and the two conformations of PBA (semi-transparent CPK colors, light blue
carbon atoms; PDB entry 6VIM, chain B). (D) Stereoview of a structural overlay of the active site of MR with the
2-FPBA/benzoxaborole adduct (CPK colors, gray carbon atoms), BzH (CPK colors, green carbon atoms; PDB
entry 3UXK, chain A), and (S)-atrolactate (CPK colors, yellow carbon atoms; PDB entry 1MRA). In panels C and D,
the water molecule marked with an asterisk is present only in the 2-FPBA/benzoxaborole adduct structure,
filling the space normally occupied by the ε − NH2 group of Lys 164 after this residue shifts its position to
directly interact with the 2-FPBA/benzoxaborole adduct. In all panels, Mg2+ is represented as a purple sphere
and water molecules are represented as red spheres.
Scheme 3

Surprisingly, 2-FPBA did not form an iminoboronate at the active site of MR (Figure 3A and Figure S4), consistent
with our inability to trap the ligand using NaCNBH3, nor did 2-FPBA form a complex similar to PBA
(Figure 3C). (29) Indeed, a clear Nζ–B interaction (1.5 Å) with Lys 166 was present, while the Nε2 atom of His 297
was 4.5 Å from the tetrahedral, sp3-hybridized boron atom. Unlike PBA (PDB entry 6VIM), (29) which
coordinated the Mg2+ ion in a bidentate fashion yielding a distorted octahedral coordination geometry, only the
single hydroxyl group of the cyclic benzoxaborole was strongly coordinated to the Mg2+ ion with a Mg2+–O
distance of 2.3 Å. The side chains of Asp 195, Glu 221, and Glu 247 and two water molecules completed the
octahedral coordination of the divalent metal ion. The active site residues Asp 197, Lys 164, His 297, and Glu
317, as well as the Mg2+-chelating residue Glu 247, all formed H-bonds with the adduct with protein–ligand
distances of ≤3.0 Å (Figure 3B). Finally, dispersion interactions between the phenyl ring and the hydrophobic
pocket at the active site of MR also contributed to the binding affinity of the 2-FPBA/benzoxaborole adduct.
Interestingly, the plane of the phenyl ring of the 2-FPBA/benzoxaborole adduct was angled approximately 31°
and 24° away from His 297 and toward Lys 166 relative to the plane of the phenyl ring of bound, sp3-hybridized
PBA participating in a Nε2–B dative bond with His 297 and the plane of the ring of sp2-hybridized PBA,
respectively (Figure 3C). Comparison of the structure of the MR-bound 2-FPBA/benzoxaborole adduct with those
structures of MR with bound (S)-atrolactate (PDB entry 1MDR) (73) and BzH (PDB entry 3UXK) (42) revealed that
one B–OH bond of the 2-FPBA/benzoxaborole adduct aligned with the C-OH group of (S)-atrolactate and BzH to
coordinate the active site Mg2+ ion. While both (S)-atrolactate and BzH interacted with the Mg2+ ion in a
bidentate fashion, the ring oxygen of the 2-FPBA/benzoxaborole adduct moved away from the metal ion to form
an H-bond with the ε − NH2 group of Lys 164 (3.1 Å) (Figure 3D).
Typically, in the structures of the MR complexes with BzH or (S)-atrolactate, the ε − NH2 group of Lys 164 is
located such that it is H-bonded to the N-hydroxy or carboxyl oxygen of the ligand, respectively. However, in the
complex with the 2-FPBA/benzoxaborole adduct, the side chain of Lys 164 occupies an unusual position, moving
to form an H-bond (3.1 Å) with the cyclic oxygen of the 2-FPBA/benzoxaborole adduct at all active sites except

for that of chain G. In chain G, the electron density was modeled for the side chain of Lys164 in two
conformations, each at 50% occupancy: one with the side chain of Lys 164 forming an H-bond with the cyclic
oxygen of the 2-FPBA/benzoxaborole adduct [with a water molecule located at the position typically occupied
by the ε − NH2 group of Lys 164 in structures with bound (S)-atrolactate or BzH] and a second conformation
with the side chain of Lys 164 in its “typical” location, forming an H-bond with the oxygen of the water molecule
coordinated to the Mg2+ ion (Figure 3C,D and Figure S4).

Mechanism of Inhibition

In solution, the anionic, tetrahedral species 4 (see Scheme 1A, vide infra) comprises ∼61% of the 2-FPBA present
at the assay pH of 7.5 (𝑝𝑝𝐾𝐾𝑎𝑎 for 2-FPBA = 7.30 ± 0.05; (67) cf. 𝑝𝑝𝐾𝐾𝑎𝑎 = 7.5 (74)). Because 2-FPBA exhibited better
inhibition with a change in pH from 7.0 to 8.0 (Table 1 and Figure S1), where MR exhibits little change in the
values of 𝑘𝑘cat and 𝐾𝐾𝑚𝑚 , (27,75) it appears that the anionic, tetrahedral benzoxaborole species 4 is preferentially
bound by the enzyme as opposed to the neutral, trigonal boronic acid species 1. Binding of 4 is not unexpected
because MR is competitively inhibited by benzoxaborole with a 𝐾𝐾𝑖𝑖 value of 3.0 ± 0.4 μM, which is similar to
the 𝐾𝐾𝑖𝑖 value for inhibition by 2-FPBA (J. A. Hayden and S. L. Bearne, unpublished results).

The observed slow-onset inhibition kinetics suggests that inhibition by 2-FPBA may occur via a two-step process
(Scheme 2A). Early studies of the reversible binding of diols with arylboronic acids showed that boronic acid
ester formation was favored at high pH where the boronate anion was the major species, leading to the notion
that adduct formation primarily occurred through the boronate anion. (76,77) However, subsequent studies
indicated that the neutral trigonal planar boronic acid species is the reactive species in solution (78−81) and that
oxaboroles can form dative bonds more readily than their corresponding phenylboronic
acids. (77) Consequently, we propose that the first step (i.e., formation of EI) is binding of the anionic,
tetrahedral benzoxaborole species 4 followed by displacement of hydroxide by the ε − NH2 group of Lys 166 to
form the Nζ–B bond and yield the E*I complex (Scheme 3A). Considering the formation of the Nζ–B bond and the
multiple H-bonds between the 2-FPBA/benzoxaborole adduct and the active site, the reverse reaction (i.e., k6) is
likely slow. However, additional studies are required to delineate the potential role of Lys 164 in the onset of
inhibition and to rule out alternative mechanisms such as initial binding of the inhibitor as neutral trigonal
species 1 with subsequent formation of an Nζ–B bond with the ε − NH2 group of Lys 166, followed by, or
concerted with, cyclization to form the cyclic 2-FPBA/benzoxaborole adduct (Scheme 3B). Indeed, because the
cyclization is slow in solution on the NMR time scale (vide supra), this process could comprise a slow step.
Importantly, although formation of an imine is favorable under our assay conditions [i.e., 𝐾𝐾obs = 85 ±
6 M –1 for imine formation between ethylamine and 2-FPBA (Figure S5)], our inability to trap an imine by
reduction suggests that it is unlikely that the slow step arises from initial imine formation followed by a
rearrangement of the orientation of 2-FPBA at the active site. We posit that the binding orientation of 2-FPBA at
the active site disfavors imine formation.

Although the CD-based assay is not a sensitive assay, fitting the kinetic data for the slow-onset inhibition of
K164R MR by 2-FPBA (Figure 1B) indicated that the bimolecular rate constant for inhibition (𝑘𝑘3 = 188 M–1 s–1)
was several orders of magnitude smaller than typical bimolecular rate constants for ES formation (105–107 M–1 s–
1
). (82) This result is consistent with more than one step being required for formation of the first detectable EI
complex, although the specific nature of those steps is not known. (34) Our observation that the binding affinity
of 2-FPBA is 3-fold weaker with the K164R variant relative to wild-type MR suggests that the Arg 164 variant
causes subtle structural perturbations at the active site due to the added steric bulk or causes alterations in Hbonding that slightly disfavor binding.

Conclusions

2-FPBA is the first slow-onset inhibitor identified for MR, exhibiting 𝐾𝐾𝑖𝑖 and 𝐾𝐾𝑖𝑖∗ values of 5.1 ± 1.8 and 0.26 ± 0.08
μM, respectively. It is among the most potent inhibitors of MR identified to date (𝐾𝐾𝑚𝑚 /𝐾𝐾𝑖𝑖∗ ≈ 3000), (29) with a
binding affinity that rivals those of transition state analogue inhibitors of the enzyme. (47,48) Most surprisingly,
rather than forming the expected iminoboronate, the ε − NH2 group of Lys 166 formed an Nζ–B dative bond
with 2-FPBA at the active site, leading to formation of a benzoxaborole adduct. Although benzoxaboroles can be
formed from reactions of amines, especially secondary amines, with the aldehyde of 2-FPBA, (83) it appears that
the formation of the observed Nζ–B-based 2-FPBA/benzoxaborole adduct is favored and facilitated by the
orientation of the bound 2-FPBA at the active site and, possibly, the reduced dielectric
environment. (18) Overall, our results indicate that when o-carbonyl arylboronic acid reagents are employed to
modify amino groups in proteins, the structure of the resulting product depends on the protein architecture at
the site of modification.
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